| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Immune and Gene Therapy Laboratory, Cancer Centre Karolinska,
Department of Urology, and
Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden; and
Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, United Kingdom
In this study, we investigated whether CD4+CD25high regulatory T cells (Treg) are increased in the tumor tissue and peripheral blood of early-stage prostate cancer patients undergoing prostatectomy. We show that the prevalence of CD4+CD25high T cells inside the prostate was significantly higher in the tumor compared with benign tissue from the same prostate. Furthermore, the frequency of CD4+CD25high T cells in peripheral blood was significantly higher in prostate cancer patients compared with normal donors. A proportion of the CD4+CD25high T cells was also shown to be glucocorticoid-induced TNF receptor, ICOS, and FOXP3 positive. Moreover, CD4+CD25+ T cells from blood and supernatants from cultured prostate tumor tissue samples exhibited immunosuppressive function in vitro. Furthermore, supernatants from cultured prostate tissue samples and prostate cancer ascites fluid induced migration of CD4+CD25+ T cells and were shown to contain the regulatory T cell chemokine CCL22 by ELISA. Our findings indicate that Tregs are an important cellular component of early-stage prostate tumors, and thus new therapeutic strategies aimed at inhibition or depletion of Tregs may improve prostate cancer immunotherapy.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported partly by grants from the Cancer Society in Stockholm, the Swedish Cancer Society, Karolinska Institute Funds, NordForsk Motility Grant 040226, EU 6-FP "ALLOSTEM" (LSHB-CT-2004-503319), EU 6-FP "ENACT," and U.S. Department of Defense Prostate Cancer Research Program (PC030958). A.H.B. is supported by the Leukemia Research Fund. A.M.M. is the recipient of a scholarship from Stockholm’s Odd Fellow-Logers.
2 Address correspondence and reprint requests to Dr. Ashley M. Miller, Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden. E-mail address: Ashley.Miller{at}ki.se
3 Abbreviations used in this paper: PC, prostate cancer; Treg, regulatory T cell; GITR, glucocorticoid-induced TNF receptor; TIL, tumor-infiltrating lymphocyte; SDF-1
, stromal cell-derived factor 1.
This article has been cited by other articles:
|
|
 |
|
  C. G. Drake Immunotherapy for Prostate Cancer: Walk, Don't Run J. Clin. Oncol., September 1, 2009; 27(25): 4035 - 4037. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wang, R. Lau, D. Yu, W. Zhu, A. Korman, and J. Weber PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells Int. Immunol., September 1, 2009; 21(9): 1065 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. TOKUNO, S. HAZAMA, S. YOSHINO, S. YOSHIDA, and M. OKA Increased Prevalence of Regulatory T-Cells in the Peripheral Blood of Patients with Gastrointestinal Cancer Anticancer Res, May 1, 2009; 29(5): 1527 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Getnet, C. H. Maris, E. L. Hipkiss, J. F. Grosso, T. J. Harris, H.-R. Yen, T. C. Bruno, S. Wada, A. Adler, R. W. Georgantas, et al. Tumor Recognition and Self-Recognition Induce Distinct Transcriptional Profiles in Antigen-Specific CD4 T Cells J. Immunol., April 15, 2009; 182(8): 4675 - 4685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Merlo, P. Casalini, M. L. Carcangiu, C. Malventano, T. Triulzi, S. Menard, E. Tagliabue, and A. Balsari FOXP3 Expression and Overall Survival in Breast Cancer J. Clin. Oncol., April 10, 2009; 27(11): 1746 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Du, L. Jin, X. Han, Z. Song, H. Zhang, and W. Liang Naringenin: A Potential Immunomodulator for Inhibiting Lung Fibrosis and Metastasis Cancer Res., April 1, 2009; 69(7): 3205 - 3212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gnjatic, N. K. Altorki, D. N. Tang, S.-M. Tu, V. Kundra, G. Ritter, L. J. Old, C. J. Logothetis, and P. Sharma NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells Clin. Cancer Res., March 15, 2009; 15(6): 2130 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. WADA, H. SUZUKI, R. FUCHINO, A. YAMASAKI, S. NAGAI, K. YANAI, K. KOGA, M. NAKAMURA, M. TANAKA, T. MORISAKI, et al. The Contribution of Vascular Endothelial Growth Factor to the Induction of Regulatory T-Cells in Malignant Effusions Anticancer Res, March 1, 2009; 29(3): 881 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gobert, I. Treilleux, N. Bendriss-Vermare, T. Bachelot, S. Goddard-Leon, V. Arfi, C. Biota, A. C. Doffin, I. Durand, D. Olive, et al. Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome Cancer Res., March 1, 2009; 69(5): 2000 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chen, C. I. Liakou, A. Kamat, C. Pettaway, J. F. Ward, D. N. Tang, J. Sun, A. A. Jungbluth, P. Troncoso, C. Logothetis, et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-{gamma} levels in both nonmalignant and malignant prostate tissues PNAS, February 24, 2009; 106(8): 2729 - 2734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wieczorek, A. Asemissen, F. Model, I. Turbachova, S. Floess, V. Liebenberg, U. Baron, D. Stauch, K. Kotsch, J. Pratschke, et al. Quantitative DNA Methylation Analysis of FOXP3 as a New Method for Counting Regulatory T Cells in Peripheral Blood and Solid Tissue Cancer Res., January 15, 2009; 69(2): 599 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ahmadzadeh, A. Felipe-Silva, B. Heemskerk, D. J. Powell Jr, J. R. Wunderlich, M. J. Merino, and S. A. Rosenberg FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions Blood, December 15, 2008; 112(13): 4953 - 4960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Koyama, H. Kagamu, S. Miura, T. Hiura, T. Miyabayashi, R. Itoh, H. Kuriyama, H. Tanaka, J. Tanaka, H. Yoshizawa, et al. Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage Clin. Cancer Res., November 1, 2008; 14(21): 6770 - 6779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Heimberger, M. Abou-Ghazal, C. Reina-Ortiz, D. S. Yang, W. Sun, W. Qiao, N. Hiraoka, and G. N. Fuller Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas Clin. Cancer Res., August 15, 2008; 14(16): 5166 - 5172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kavanagh, S. O'Brien, D. Lee, Y. Hou, V. Weinberg, B. Rini, J. P. Allison, E. J. Small, and L. Fong CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion Blood, August 15, 2008; 112(4): 1175 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schaue, B. Comin-Anduix, A. Ribas, L. Zhang, L. Goodglick, J. W. Sayre, A. Debucquoy, K. Haustermans, and W. H. McBride T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy Clin. Cancer Res., August 1, 2008; 14(15): 4883 - 4890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Sfanos, T. C. Bruno, C. H. Maris, L. Xu, C. J. Thoburn, A. M. DeMarzo, A. K. Meeker, W. B. Isaacs, and C. G. Drake Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing Clin. Cancer Res., June 1, 2008; 14(11): 3254 - 3261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Strauss, C. Bergmann, M. J. Szczepanski, S. Lang, J. M. Kirkwood, and T. L. Whiteside Expression of ICOS on Human Melanoma-Infiltrating CD4+CD25highFoxp3+ T Regulatory Cells: Implications and Impact on Tumor-Mediated Immune Suppression J. Immunol., March 1, 2008; 180(5): 2967 - 2980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yokokawa, V. Cereda, C. Remondo, J. L. Gulley, P. M. Arlen, J. Schlom, and K. Y. Tsang Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer Clin. Cancer Res., February 15, 2008; 14(4): 1032 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Goldstein, L. Mascitelli, and F. Pezzetta How Statins May Increase Prostate Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 459 - 459. [Full Text] [PDF]
|
|
|
|
|
|
E. Degl'Innocenti, M. Grioni, G. Capuano, E. Jachetti, M. Freschi, M. T.S. Bertilaccio, R. Hess-Michelini, C. Doglioni, and M. Bellone Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells Cancer Res., January 1, 2008; 68(1): 292 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kiniwa, Y. Miyahara, H. Y. Wang, W. Peng, G. Peng, T. M. Wheeler, T. C. Thompson, L. J. Old, and R.-F. Wang CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer Clin. Cancer Res., December 1, 2007; 13(23): 6947 - 6958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Schreiber The Use of FoxP3 as a Biomarker and Prognostic Factor for Malignant Human Tumors Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1931 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Kang, H. W. Lim, O. M. Andrisani, H. E. Broxmeyer, and C. H. Kim Vitamin A Metabolites Induce Gut-Homing FoxP3+ Regulatory T Cells J. Immunol., September 15, 2007; 179(6): 3724 - 3733. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
